Regorafenib combined with programmed cell death-1 inhibitor against refractory colorectal cancer and the platelet-to-lymphocyte ratio’s prediction on effectiveness

Figure 2 Receiver operating characteristics curves. A: The receiver operating characteristics curves of neutrophil-to-lymphocyte ratio; B: The receiver operating characteristics curves of platelet-to-lymphocyte ratio. NLR: Platelet -to-lymphocyte ratio; PLR: Neutrophil-to-lymphocyte ratio; ROC: Receiver operating characteristics.